• Current through October 23, 2012

(a) The AccessRx Fund is established as a nonlapsing, dedicated fund, into which shall be deposited revenue from manufacturers and labelers that pay rebates pursuant to this subchapter and any appropriations or allocations designated for the AccessRx Fund, along with accruing interest, to be used for the purposes specified in subsection (b) of this section.

(b) All funds in the AccessRx Fund, including any surplus or interest, shall be used to:

(1) Reimburse retail pharmacies for discounted prices provided to uninsured qualified residents pursuant to § 48-831.33;

(2) Pay benefits described in § 48-831.23; and

(3) Reimburse the Department for contracted services, including pharmacy claims processing fees, administrative and associated computer costs, and other reasonable program costs.

(c) The funds deposited in the AccessRx Fund shall not revert to the General Fund but shall continually be available for the uses designated in subsection (b) of this section, subject to authorization by Congress in an appropriations act.

(May 18, 2004, D.C. Law 15-164, § 110, 51 DCR 3688; Mar. 2, 2007, D.C. Law 16-191, § 88(a), 53 DCR 6794.)


Effect of Amendments

D.C. Law 16-191, in subsec. (b)(1), validated a previously made technical correction.

Legislative History of Laws

For Law 15-164, see notes following § 48-831.01.

Law 16-191, the "Technical Amendments Act of 2006", was introduced in Council and assigned Bill No. 16-760, which was referred to the Committee of the whole. The Bill was adopted on first and second readings on June 20, 2006, and July 11, 2006, respectively. Signed by the Mayor on July 31, 2006, it was assigned Act No. 16-475 and transmitted to both Houses of Congress for its review. D.C. Law 16-191 became effective on March 2, 2007.